Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121228:nBw285477a

PRINCETON, N.J. & NEW YORK--(Business Wire)--
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today
announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS®
(apixaban).

Please see full Prescribing Information including BOXED WARNING and Medication
Guide available at www.bms.com.

Bristol-Myers Squibb and Pfizer will provide additional information on the FDA
approval of Eliquis in a separate press release, to be issued next week.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit http://www.bms.com or
follow us on Twitter at http://twitter.com/bmsnews.

Pfizer Inc.: Working together for a healthier world

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, as well as
many of the world`s best-known consumer products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as the world`s leading biopharmaceutical
company, we also collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable health care
around the world. For more than 150 years, Pfizer has worked to make a
difference for all who rely on us.

Bristol-Myers Squibb
Media:
Laura Hortas, 609-240-7025
Laura.hortas@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
Ranya.Dajani@bms.com
or
Ryan Asay, 609-252-5020
Ryan.Asay@bms.com
or
Pfizer Inc.
Media:
MacKay Jimeson, 212-733-2324
MacKay.Jimeson@pfizer.com
or
Investors:
Suzanne Harnett, 212-733-8009
Suzanne.Harnett@pfizer.com

Copyright Business Wire 2012